Atlas Trials

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Clinical trial NCT02189837 · COMPLETED

Trial details

NCT number
NCT02189837
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Hyperlipidemia and Mixed Dyslipidemia
Start date
2014-07-08
Primary completion
2015-02-13
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.